Delayed generalized inflammatory psoriasis flare during efalizumab treatment

British Journal of Dermatology

Volumn 161, Issue 1, 2009, Pages 212-213

  Martin, B ^a   Sanchez Carazo J L ^a   Perez Ferriols A ^a   Oliver, V ^a   Alegre, V ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Biologic therapy; Efalizumab; Psoriasis

Indexed keywords

CORTICOSTEROID; EFALIZUMAB; METHOTREXATE; PSORALEN;

ADULT; ANAMNESIS; ARTHRALGIA; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; DELAYED GENERALIZED INFLAMMATORY PSORIASIS FLARE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LETTER; LYMPHOCYTE MIGRATION; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SCORING SYSTEM; SKIN INFLAMMATION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PSORIASIS; TIME FACTORS; YOUNG ADULT;

EID: 67649986287     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09223.x     Document Type: Letter

References (7)

1. Gottlieb A, Hamilton T, Caro I et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006 54 : 154 63.
2. Carey W, Glazer S, Gottlieb A et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006 54 : 171 81.
3. Menter A, Leonardo C, Sterry W. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006 54 : 182 8.
4. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007 26 : 6 14. (Pubitemid 46349778)
5. Hamilton TK. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 2005 24 : 19 27. (Pubitemid 40410095)
6. Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report. Acta Derm Venereol (Stockh) 2006 86 : 456 7.
7. Pincelli C, Henninger E, Casset-Semanaz F. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from phase III clinical trials of efalizumab. Arch Dermatol Res 2006 298 : 329 38.